Editas Medicine posts smaller‑than‑expected Q4 net loss on lower R&D spend

Editas Medicine, Inc. +4.18%

Editas Medicine, Inc.

EDIT

3.49

+4.18%


Overview

  • Gene editing firm's Q4 net loss beat analyst estimates

  • Collaboration and R&D revenue decreased due to prior milestone revenue recognition

  • Company maintains strong cash position with runway into Q3 2027


Outlook

  • Editas plans IND/CTA submission for EDIT-401 by mid-2026


Result Drivers

  • LOWER R&D EXPENSE: Research and development expenses decreased by $21.2 million to $27.4 million for the three months ended December 31, 2025, compared to $48.6 million for the same period in 2024.


Company press release: ID:nGNX8VPqVz


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Collaboration and other research and development revenue

$24.70 mln

Q4 EPS

-$0.06

Q4 Net Income

Beat

-$5.62 mln

-$24.29 mln (9 Analysts)

Q4 Basic EPS

-$0.06

Q4 Operating Expenses

$32.50 mln

Q4 Operating Income

-$7.76 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 5 "hold" and 2 "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Editas Medicine Inc is $4.00, about 100% above its March 6 closing price of $2.00


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.